KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Operating Expenses (2017 - 2025)

Aquestive Therapeutics has reported Operating Expenses over the past 9 years, most recently at $41.9 million for Q4 2025.

  • Quarterly results put Operating Expenses at $41.9 million for Q4 2025, up 64.48% from a year ago — trailing twelve months through Dec 2025 was $115.6 million (up 30.87% YoY), and the annual figure for FY2025 was $115.6 million, up 30.87%.
  • Operating Expenses for Q4 2025 was $41.9 million at Aquestive Therapeutics, up from $24.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for AQST hit a ceiling of $41.9 million in Q4 2025 and a floor of $15.4 million in Q3 2023.
  • Median Operating Expenses over the past 5 years was $21.4 million (2022), compared with a mean of $22.2 million.
  • Biggest five-year swings in Operating Expenses: tumbled 32.95% in 2023 and later surged 64.48% in 2025.
  • Aquestive Therapeutics' Operating Expenses stood at $22.7 million in 2021, then dropped by 5.94% to $21.4 million in 2022, then fell by 20.0% to $17.1 million in 2023, then soared by 48.66% to $25.4 million in 2024, then surged by 64.48% to $41.9 million in 2025.
  • The last three reported values for Operating Expenses were $41.9 million (Q4 2025), $24.3 million (Q3 2025), and $21.4 million (Q2 2025) per Business Quant data.